ERAS
Price
$3.43
Change
+$0.04 (+1.18%)
Updated
Dec 24 closing price
Capitalization
973.13M
84 days until earnings call
Intraday BUY SELL Signals
OCUL
Price
$12.71
Change
-$0.03 (-0.24%)
Updated
Dec 24 closing price
Capitalization
2.71B
74 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ERAS vs OCUL

Header iconERAS vs OCUL Comparison
Open Charts ERAS vs OCULBanner chart's image
Erasca
Price$3.43
Change+$0.04 (+1.18%)
Volume$1.23M
Capitalization973.13M
Ocular Therapeutix
Price$12.71
Change-$0.03 (-0.24%)
Volume$922.36K
Capitalization2.71B
ERAS vs OCUL Comparison Chart in %
ERAS
Daily Signal:
Gain/Loss:
OCUL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ERAS vs. OCUL commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and OCUL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (ERAS: $3.43 vs. OCUL: $12.71)
Brand notoriety: ERAS and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 63% vs. OCUL: 31%
Market capitalization -- ERAS: $973.13M vs. OCUL: $2.71B
ERAS [@Biotechnology] is valued at $973.13M. OCUL’s [@Biotechnology] market capitalization is $2.71B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 2 TA indicator(s) are bullish while OCUL’s TA Score has 5 bullish TA indicator(s).

  • ERAS’s TA Score: 2 bullish, 5 bearish.
  • OCUL’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, OCUL is a better buy in the short-term than ERAS.

Price Growth

ERAS (@Biotechnology) experienced а -5.77% price change this week, while OCUL (@Biotechnology) price change was -7.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

ERAS is expected to report earnings on Mar 19, 2026.

OCUL is expected to report earnings on Mar 09, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.71B) has a higher market cap than ERAS($973M). OCUL YTD gains are higher at: 48.829 vs. ERAS (36.653). ERAS has higher annual earnings (EBITDA): -131.32M vs. OCUL (-233.54M). OCUL has more cash in the bank: 345M vs. ERAS (288M). ERAS has less debt than OCUL: ERAS (48.3M) vs OCUL (77M). OCUL has higher revenues than ERAS: OCUL (55.8M) vs ERAS (0).
ERASOCULERAS / OCUL
Capitalization973M2.71B36%
EBITDA-131.32M-233.54M56%
Gain YTD36.65348.82975%
P/E RatioN/AN/A-
Revenue055.8M-
Total Cash288M345M83%
Total Debt48.3M77M63%
FUNDAMENTALS RATINGS
OCUL: Fundamental Ratings
OCUL
OUTLOOK RATING
1..100
66
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
44
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASOCUL
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 9 days ago
81%
Bullish Trend 18 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signal:
Gain/Loss:
OCUL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DGYGX35.380.07
+0.20%
BNY Mellon Appreciation Y
PSKCX24.770.01
+0.04%
Virtus KAR Mid-Cap Growth C
FCTGX30.91N/A
N/A
Fidelity Advisor Small Cap Growth M
CDGRX12.34N/A
N/A
Copeland Dividend Growth Fund Class A
SOAVX38.47N/A
N/A
Spirit of America Large Cap Value A

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+1.18%
RVMD - ERAS
51%
Loosely correlated
+1.15%
EYPT - ERAS
50%
Loosely correlated
-0.65%
XNCR - ERAS
50%
Loosely correlated
-0.13%
OCUL - ERAS
49%
Loosely correlated
-0.24%
CLDX - ERAS
46%
Loosely correlated
+0.94%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with WVE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then WVE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-0.24%
WVE - OCUL
56%
Loosely correlated
+4.41%
NRIX - OCUL
54%
Loosely correlated
+0.36%
KYMR - OCUL
52%
Loosely correlated
-0.48%
IDYA - OCUL
51%
Loosely correlated
+0.76%
EYPT - OCUL
51%
Loosely correlated
-0.65%
More